MKK4 is a novel target for the inhibition of tumor necrosis factor-α-induced vascular endothelial growth factor expression by myricetin

Biochemical Pharmacology

Volumn 77, Issue 3, 2009, Pages 412-421

  Kim, Jong Eun ^a   Kwon, Jung Yeon ^b   Lee, Dong Eun ^a   Kang, Nam Joo ^a,b   Heo, Yong Seok ^b   Lee, Ki Won ^b   Lee, Hyong Joo ^a  

^a Seoul National University   (South Korea)

^b Konkuk University   (South Korea)

Author keywords

Mitogen activated protein kinase kinase 4; Myricetin; Vascular endothelial growth factor

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ADENOSINE TRIPHOSPHATE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; GLUTATHIONE TRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MYRICETIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; CELL TRANSFORMATION; COMPUTER MODEL; CONTROLLED STUDY; ENZYME ACTIVITY; EPIDERMIS CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL; UPREGULATION;

ANIMALS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLAVONOIDS; IMMUNOPRECIPITATION; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, MOLECULAR; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 58249129942     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.10.027     Document Type: Article

References (32)

1. Tweedie D., Sambamurti K., and Greig N.H. TNF-inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Current Alzheimer Research 4 (2007) 378-385
2. Clark I.A. How TNF was recognized as a key mechanism of disease. Cytokine & Growth Factor Reviews 18 (2007) 335-343
3. Feldmann M., and Maini R.N. Anti-TNFα therapy of rheumatoid arthritis: what have we learned?. Annual Review of Immunology (2001) 163-196
4. Takada Y., and Aggarwal B.B. Flavopiridol inhibits NF-κB activation induced by various carcinogens and inflammatory agents through inhibition of IκBα kinase and p65 phosphorylation. Abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. Journal of Biological Chemistry 279 (2004) 4750-4759
5. Chen C.C., Chow M.P., Huang W.C., Lin Y.C., and Chang Y.J. Flavonoids inhibit tumor necrosis factor-α-induced up-regulation of intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells through activator protein-1 and nuclear factor-κB: Structure-activity relationships. Molecular Pharmacology 66 (2004) 683-693
6. Manna S.K., Mukhopadhyay A., Van N.T., and Aggarwal B.B. Silymarin suppresses TNF-induced activation of NF-κB, c-Jun N-terminal kinase, and apoptosis. Journal of Immunology 163 (1999) 6800-6809
7. Paneas J., Gerritsen M.E., Anderson D.C., Miyasaka M., and Granger D.N. Apigenin inhibits tumor necrosis factor-induced intercellular adhesion molecule-1 upregulation in vivo. Microcirculation 3 (1996) 279-286
8. Wajant H., Pfizenmaier K., and Scheurich P. Tumor necrosis factor signaling. Cell Death and Differentiation 10 (2003) 45-65
9. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews 25 (2004) 581-611
10. Joseko J., and Mazurek M. Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. Medical Science Monitor (2004) 10
11. Huang C., Li J., Song L., Zhang D., Tong Q., Ding M., et al. Black raspberry extracts inhibit benzo(a)pyrene diol-epoxide-induced activator protein 1 activation and VEGF transcription by targeting the phosphotidylinositol 3-kinase/Akt pathway. Cancer Research 66 (2006) 581-587
12. Lee C.C., Chen S.C., Tsai S.C., Wang B.W., Liu Y.C., Lee H.M., et al. Hyperbaric oxygen induces VEGF expression through ERK, JNK and c-Jun/AP-1 activation in human umbilical vein endothelial cells. Journal of Biomedical Science 13 (2006) 143-156
13. Harnly J.M., Doherty R.F., Beecher G.R., Holden J.M., Haytowitz D.B., Bhagwat S., et al. Flavonoid content of U.S. fruits, vegetables, and nuts. Journal of Agricultural and Food Chemistry 54 (2006) 9966-9977
14. Pietta P.G. Flavonoids as antioxidants. Journal of Natural Products 63 (2000) 1035-1042
15. Kempuraj D., Madhappan B., Christodoulou S., Boucher W., Cao J., Papadopoulou N., et al. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. British Journal of Pharmacology 145 (2005) 934-944
16. Mukhtar H., Das M., Khan W.A., Wang Z.Y., Bik D.P., and Bickers D.R. Exceptional activity of tannic acid among naturally occurring plant phenols in protecting against 7,12-dimethylbenz(a)anthracene-, benzo(a)pyrene-, 3-methylcholanthrene-, and N-methyl-N-nitrosourea-induced skin tumorigenesis in mice. Cancer Research 48 (1988) 2361-2365
17. Lu J., Papp L.V., Fang J., Rodriguez-Nieto S., Zhivotovsky B., and Holmgren A. Inhibition of mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Research 66 (2006) 4410-4418
18. Williams R.J., Spencer J.P.E., and Rice-Evans C. Flavonoids: antioxidants or signalling molecules?. Free Radical Biology and Medicine 36 (2004) 838-849
19. Walker E.H., Pacold M.E., Perisic O., Stephens L., Hawkins P.T., Wymann M.P., et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Molecular Cell 6 (2000) 909-919
20. Holder S., Zemskova M., Zhang C., Tabrizizad M., Bremer R., Neidigh J.W., et al. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Molecular Cancer Therapeutics 6 (2007) 163-172
21. Lee K.W., Kang N.J., Rogozin E.A., Kim H.-G., Cho Y.Y., Bode A.M., et al. Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis 28 (2007) 1918-1927
22. Huang C., Li J., Ma W.Y., and Dong Z. JNK activation is required for JB6 cell transformation induced by tumor necrosis factor-α but not by 12-O-tetradecanoylphorbol-13-acetate. Journal of Biological Chemistry 274 (1999) 29672-29676
23. Whitmarsh A.J., and Davis R.J. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene 26 (2007) 3172-3184
24. Lee K.W., Kang N.J., Heo Y.-S., Rogozin E.A., Pugliese A., Hwang M.K., et al. Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Research 68 (2008) 946-955
25. Eferl R., and Wagner E.F. AP-1: a double-edged sword in tumorigenesis. Nature Reviews Cancer 3 (2003) 859-868
26. Shaulian E., and Karin M. AP-1 as a regulator of cell life and death. Nature Cell Biology (2002) 4
27. Jaeschke A., Karasarides M., Ventura J.-J., Ehrhardt A., Zhang C., Flavell R.A., et al. JNK2 is a positive regulator of the cJun transcription factor. Molecular Cell 23 (2006) 899-911
28. Weston C.R., and Davis R.J. The JNK signal transduction pathway. Current Opinion in Genetics and Development 12 (2002) 14-21
29. Brancho D., Tanaka N., Jaeschke A., Ventura J.J., Kelkar N., Tanaka Y., et al. Mechanism of p38 MAP kinase activation in vivo. Genes and Development 17 (2003) 1969-1978
30. Harrington L.S., Findlay G.M., and Lamb R.F. Restraining PI3K: mTOR signalling goes back to the membrane. Trends in Biochemical Sciences 30 (2005) 35-42
31. Watts R.G., Huang C., Young M.R., Li J.J., Dong Z., Pennie W.D., et al. Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation. Oncogene 17 (1998) 3493-3498
32. Vogt P.K., and Kang S. Kinase inhibitors: vice becomes virtue. Cancer Cell 9 (2006) 327-328